AlfaSight™ 9000

The AlfaSight™ 9000 is a state-of-the-art health testing system that identifies physiological dysfunction very early in the disease process. Using a subtle thermal stress stimulus that initiates a regulation response, underlying disturbances and dysfunctional organ systems are revealed with a high degree of accuracy.

This whole-body thermometry system employs the science of regulation thermography, and employs data from more than 100,000 patient assessments over the past three decades. Disease signatures have been derived from the data and correlated with nuclear-CT (SPECT) and MRI studies that were performed by Dr. David Hickey, radiologist and a member of the Alfa Medical Team, in his Dallas-based imaging center.

Feedback provided by AlfaSight™ allows physicians to make more accurate and real-time assessments of the root cause of a disease and accompanying factors. More focused laboratory or imaging tests can then be prescribed for a more efficient and cost-effective approach to diagnosis.

AlfaSight™ also recognizes trends in the body that can assist in the practice of preventive medicine.

Specific areas of physiological dysfunction that can be identified include:

• Abnormalities of the female breast
• Peripheral vascular disease
• Musculoskeletal disorders
• Extracranial cerebral and facial vascular disease
• Abnormalities of the thyroid gland
• Various neoplastic and inflammatory conditions

Parallel disease factors accompanying many conditions such as heart disease, diabetes, cognitive disorders and viral diseases are also identified. Early stage detection of these factors is critical for effective treatment and faster recoveries.

 How it Works

Case Study – SU – 2018

CASE REVIEW: RETURN OF A BREAST CANCER 20 YEARS POST CHEMO/RADIATION/LUMPECTOMY, DISCOVERED BY ALFA THERMOMETRY

In most cases, breast cancer in remission over 10 years means permanent remission. This is true especially in women far past their menopausal shift (ages 65-and on).

A 63 yo woman w history of left breast cancer completed mastectomy in 1996, followed by brief chemotherapy and radiation, along with integrative care.

Yearly follow-up mammography, with periodic bone scans and laboratory findings continued to be negative for 22 years. Her visits to obtain any form of imaging or laboratory work decreased as she was further from the initial diagnosis and treatment. She neglected to obtain integrative care as the years progressed, as well.

Recently she came in for a ‘routine’ thermometry (AlfaSight) scan. Noted was increased criteria for suspicion (7/12) and a blocked spot on the right breast at 11:00 with a clear sternum point paradox (inflammatory signature). Tooth 28 (4.4 intl) was noted to be differing in temperature respective of its neighboring teeth, as this is connected through the meridian system to the right breast. Lymphatic load was also blocked 38.5%.

The patient was referred to mammography, even when the patient was averse to routine mammography due to radiation exposure. Result was positive for a small 4mm mass at 11:00 on the right breast. She simultaneously received an ultrasound showing positive for a suspicious mass at the same location.

Her physician advised observation for growth during the next 6 months. Although given the case and the patient’s predisposition to non-invasive therapies, recommended was biopsy or lumpectomy.

Many women who come to see integrative doctors (as well as conventional) are averse to mammography. Alfasight, with its multi-faceted and multi-angled analysis of physiological processes within certain anatomical locations can be said to fill the window of what is missing in patient compliance as well as filling the gap of patients who are suddenly taken out of the constant monitoring of their physicians due to wrong expectations, and may provide a vital avenue of increased accuracy, low cost methods of monitoring women’s health.

FDA Clearance

The AlfaSight 9000TM received 510(K) clearance through the FDA Division of Radiological Health.

Indications for Use

The AlfaSight 9000TM is cleared for marketing and sales in the United States for the adjunct diagnosis of:

• abnormalities of the female breast
• peripheral vascular disease
• musculoskeletal disorders
• extra-cranial cerebral and facial vascular disease
• abnormalities of the thyroid gland
• various neoplastic and inflammatory conditions

The AlfaSight 9000TM is not intended to serve as a sole diagnostic screening procedure. It is intended as an adjunct diagnostic device only. Thermometry is not a replacement for Mammography or any other imaging method, rather it is to be used in conjunction with conventional testing to provide a physiological perspective.